Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials-Reference-Cited by-同舟云学术

Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials

Published:2019-04 Issue: Volume:200 Page:161-168
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Khurana Rahul N.,Rahimy Ehsan,Joseph W. Anthony,Saroj Namrata,Gibson Andrea,Vitti Robert,Berliner Alyson J.,Chu Karen,Cheng YenChieh,Boyer David S.

Funder

Santen

Regeneron Pharmaceuticals

Allergan

Publisher

Elsevier BV

Subject

Ophthalmology

Reference13 articles.

1. Clinical application of therapies targeting VEGF;Yancopoulos;Cell,2010

2. VEGF-A: a critical regulator of blood vessel growth;Ferrara;Eur Cytokine Netw,2009

3. Vascular endothelial growth factor a in intraocular vascular disease;Miller;Ophthalmology,2013

4. Treatment for neovascular age related macular degeneration: the state of the art;Eandi;Eur J Pharmacol,2016

5. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration;Heier;Ophthalmology,2012

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing;Advances in Therapy;2024-01-06

2. Long Intervals between Intravitreal Injections Using a Treat-and-Extend Protocol in a Real-Life Context in AMD: The LIRE Study;Ophthalmologica;2023-12-15

3. Long‐Acting Ocular Injectables: Are We Looking In The Right Direction?;Advanced Science;2023-11-28

4. Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis;Clinical Ophthalmology;2023-09

5. Home vision monitoring in patients with maculopathy: current and future options for digital technologies;Eye;2023-03-27